Xyall has launched its Tissector High Throughput (HT) system for greater precision diagnostics, enabling high-volume, molecular diagnostic laboratories to capitalise on the company’s automated, tissue dissection technology.
“Xyall has already won contracts for built-to-order systems from two of the largest laboratories in the USA, with high levels of interest from other molecular diagnostic laboratories requiring industrial-sized platforms,” said Guido Du Pree, Xyall’s CEO. “The first system is now completing its final test run before being shipped out.”
Tissue dissection, even in large-scale commercial laboratories, remains a manual, labour-intensive process at risk of error and cross contamination. “The Xyall solution provides the missing link for customers,” explained Du Pree.
“With new therapies coming to the market, and transformative technologies in PCR and next-generation sequencing, precision medicine is being revolutionised, providing physicians and patients with the highest quality information about their health.
“However, tissue dissection to enable molecular profiling is still a labour-intense, subjective process. Our pioneering technology transforms how this is done, delivering greater accuracy, consistency and overall improved quality control.”
Alongside the new large-scale, industrial system, Xyall is developing a smaller, tabletop version for hospital-based molecular pathology laboratories. Based on the same technology, the company expects to have this second system commercially available early in 2022.
Mr Du Pree added: “Worldwide shortages of experienced pathology staff are already putting laboratories under pressure. The Xyall solution will address this, helping customers to make more efficient use of existing, and increasingly scarce, staffing levels.”
